These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15685199)

  • 1. Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor.
    Fox A; Kaur S; Li B; Panesar M; Saha U; Davis C; Dragoni I; Colley S; Ritchie T; Bevan S; Burgess G; McIntyre P
    Br J Pharmacol; 2005 Apr; 144(7):889-99. PubMed ID: 15685199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958.
    Hawkinson JE; Szoke BG; Garofalo AW; Hom DS; Zhang H; Dreyer M; Fukuda JY; Chen L; Samant B; Simmonds S; Zeitz KP; Wadsworth A; Liao A; Chavez RA; Zmolek W; Ruslim L; Bova MP; Holcomb R; Butelman ER; Ko MC; Malmberg AB
    J Pharmacol Exp Ther; 2007 Aug; 322(2):619-30. PubMed ID: 17470643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antinociceptive pharmacology of N-[[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]methyl]-2-[2-[[(4-methoxy-2,6-dimethylphenyl) sulfonyl]methylamino]ethoxy]-N-methylacetamide, fumarate (LF22-0542), a novel nonpeptidic bradykinin B1 receptor antagonist.
    Porreca F; Vanderah TW; Guo W; Barth M; Dodey P; Peyrou V; Luccarini JM; Junien JL; Pruneau D
    J Pharmacol Exp Ther; 2006 Jul; 318(1):195-205. PubMed ID: 16565167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SSR240612 [(2R)-2-[((3R)-3-(1,3-benzodioxol-5-yl)-3-[[(6-methoxy-2-naphthyl)sulfonyl]amino]propanoyl)amino]-3-(4-[[2R,6S)-2,6-dimethylpiperidinyl]methyl]phenyl)-N-isopropyl-N-methylpropanamide hydrochloride], a new nonpeptide antagonist of the bradykinin B1 receptor: biochemical and pharmacological characterization.
    Gougat J; Ferrari B; Sarran L; Planchenault C; Poncelet M; Maruani J; Alonso R; Cudennec A; Croci T; Guagnini F; Urban-Szabo K; Martinolle JP; Soubrié P; Finance O; Le Fur G
    J Pharmacol Exp Ther; 2004 May; 309(2):661-9. PubMed ID: 14747609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absence of diabetic hyperalgesia in bradykinin B1 receptor-knockout mice.
    Gabra BH; Merino VF; Bader M; Pesquero JB; Sirois P
    Regul Pept; 2005 Apr; 127(1-3):245-8. PubMed ID: 15680494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological characterization and radioligand binding properties of a high-affinity, nonpeptide, bradykinin B1 receptor antagonist.
    Ransom RW; Harrell CM; Reiss DR; Murphy KL; Chang RS; Hess JF; Miller PJ; O'Malley SS; Hey PJ; Kunapuli P; Su DS; Markowitz MK; Wallace MA; Raab CE; Jones AN; Dean DC; Pettibone DJ; Freidinger RM; Bock MG
    Eur J Pharmacol; 2004 Sep; 499(1-2):77-84. PubMed ID: 15363953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From bradykinin B2 receptor antagonists to orally active and selective bradykinin B1 receptor antagonists.
    Barth M; Bondoux M; Luccarini JM; Peyrou V; Dodey P; Pruneau D; Massardier C; Paquet JL
    J Med Chem; 2012 Mar; 55(6):2574-84. PubMed ID: 22369198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF-alpha and IL-1beta mediate inflammatory hypernociception in mice triggered by B1 but not B2 kinin receptor.
    Cunha TM; Verri WA; Fukada SY; Guerrero AT; Santodomingo-Garzón T; Poole S; Parada CA; Ferreira SH; Cunha FQ
    Eur J Pharmacol; 2007 Nov; 573(1-3):221-9. PubMed ID: 17669394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aryl sulfonamides containing tetralin allylic amines as potent and selective bradykinin B1 receptor antagonists.
    Liu Q; Qian W; Li A; Biswas K; Chen JJ; Fotsch C; Han N; Yuan C; Arik L; Biddlecome G; Johnson E; Kumar G; Lester-Zeiner D; Ng GY; Hungate RW; Askew BC
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4593-7. PubMed ID: 20573508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
    Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
    Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain.
    Walker KM; Urban L; Medhurst SJ; Patel S; Panesar M; Fox AJ; McIntyre P
    J Pharmacol Exp Ther; 2003 Jan; 304(1):56-62. PubMed ID: 12490575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of kinin B1 receptors in the nociception produced by peripheral protein kinase C activation in mice.
    Ferreira J; Trichês KM; Medeiros R; Cabrini DA; Mori MA; Pesquero JB; Bader M; Calixto JB
    Neuropharmacology; 2008 Mar; 54(3):597-604. PubMed ID: 18164734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
    Schiene K; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral antinociceptive effects of mu- and delta-opioid receptor agonists in NOS2 and NOS1 knockout mice during chronic inflammatory pain.
    Leánez S; Hervera A; Pol O
    Eur J Pharmacol; 2009 Jan; 602(1):41-9. PubMed ID: 19041302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kinin system mediates hyperalgesia through the inducible bradykinin B1 receptor subtype: evidence in various experimental animal models of type 1 and type 2 diabetic neuropathy.
    Gabra BH; Berthiaume N; Sirois P; Nantel F; Battistini B
    Biol Chem; 2006 Feb; 387(2):127-43. PubMed ID: 16497144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of kinin B1 and B2 receptors in skin cancer pain produced by orthotopic melanoma inoculation in mice.
    Fujita M; Andoh T; Ohashi K; Akira A; Saiki I; Kuraishi Y
    Eur J Pain; 2010 Jul; 14(6):588-94. PubMed ID: 19932979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired nociception and peripheral opioid antinociception in mice lacking both kinin B1 and B2 receptors.
    Cayla C; Labuz D; Machelska H; Bader M; Schäfer M; Stein C
    Anesthesiology; 2012 Feb; 116(2):448-57. PubMed ID: 22273860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced nerve injury-induced neuropathic pain in kinin B1 receptor knock-out mice.
    Ferreira J; Beirith A; Mori MA; Araújo RC; Bader M; Pesquero JB; Calixto JB
    J Neurosci; 2005 Mar; 25(9):2405-12. PubMed ID: 15745967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bradyzide, a potent non-peptide B(2) bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia.
    Burgess GM; Perkins MN; Rang HP; Campbell EA; Brown MC; McIntyre P; Urban L; Dziadulewicz EK; Ritchie TJ; Hallett A; Snell CR; Wrigglesworth R; Lee W; Davis C; Phagoo SB; Davis AJ; Phillips E; Drake GS; Hughes GA; Dunstan A; Bloomfield GC
    Br J Pharmacol; 2000 Jan; 129(1):77-86. PubMed ID: 10694205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The bradykinin B1 receptor antagonist BI113823 reverses inflammatory hyperalgesia by desensitization of peripheral and spinal neurons.
    Schuelert N; Just S; Corradini L; Kuelzer R; Bernloehr C; Doods H
    Eur J Pain; 2015 Jan; 19(1):132-42. PubMed ID: 25088373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.